Persistent and dormant tubercle bacilli and latent tuberculosis

Frontiers in Bioscience

Volumn 9, Issue , 2004, Pages 1136-1156

  Zhang, Ying ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Dormancy; Mycobacterium; Persistence; Resuscitation; Review; Tuberculosis

Indexed keywords

ALPHA CRYSTALLIN; ANTIBODY; CYCLOPROPANE FATTY ACYL PHOSPHOLIPID SYNTHASE; DNA VACCINE; GLYCINE DEHYDROGENASE; IMMUNOMODULATING AGENT; ISOCITRATE LYASE; ISONIAZID; NEUROENDOCRINE SPECIFIC PROTEIN; PROTEIN DEVR; PROTEIN DEVS; PROTEIN DOSR; PROTEIN NARG; PROTEIN NARK2; PROTEIN NARX; PROTEIN PE PGRS; PROTEIN RV3133; PROTEIN SIGB; PROTEIN SIGF; PROTEIN SUBUNIT; PYRAZINAMIDE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; RIFAMPICIN; TRANSCRIPTION FACTOR RELA; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CHEMOTHERAPY; CROHN DISEASE; DORMANCY; DRUG SENSITIVITY; GROWTH INHIBITION; HOST RESISTANCE; HUMAN; IMMUNITY; INFECTION CONTROL; LATENT PERIOD; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENICITY; RHEUMATOID ARTHRITIS; SHORT SURVEY; TREATMENT INDICATION; TUBERCULOSIS; DRUG EFFECT; MICROBIOLOGY; PHYSIOLOGY; REVIEW;

BACILLI; BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VIRULENCE FACTORS;

EID: 2442711824     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1291     Document Type: Short Survey

References (221)

1. Dye, C., S. Scheele, P. Dolin, V. Pathania & M. C. Raviglione: Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 282, 677-686 (1999)
2. The World Health Organization Global Tuberculosis Program. http://www.who.int/gtb/ (last accessed 6/03)
3. McDermott, W.: Microbial persistence. The Yale J. Biol. Med. 30, 257-291 (1958)
4. Rhen, M., S. Eriksson, M. Clements, S. Bergstrom & S. J. Normark: The basis of persistent bacterial infections. Trends Microbiol. 11, 80-86 (2003)
5. Kell, D.B., A. S. Kaprelyants, D. H., Weichart, C. L. Harwood & M. R. Barer: Viability and activity in readily culturable bacteria: a review and discussion of the practical issues. Antonie Van Leeuwenhoek 73, 169-187 (1998)
6. Kell, D. B. & M. Young: Bacterial dormancy and culturability: the role of autocrine growth factors. Curr. Opin. Microbiol. 3, 238-243 (2000)
7. Barer, M. R. & C. R. Harwood: Bacterial viability and culturability. Adv. Microb. Physiol. 41, 93-137 (1999)
8. Colwell R. R..: Bacterial death revisited, in Nonculturable Microorganisms in the Environment. Ed., Rita R. Colwell and D. Jay Grimes, p. 325-342, ASM Press, Washington, D.C. (2000)
9. Nystrom, T.: Not quite dead enough: on bacterial life, culturability, senescence, and death. Arch. Microbiol. 176, 159-164 (2001)
10. Wayne, L. G.: Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13, 908-914 (1994).
11. Wayne, L. G. & C. D. Sohaskey: Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139-163 (2001)
12. Parrish, N. M., J. D. Dick & W. R. Bishai: Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 6, 107-112 (1998)
13. Honer zu Bentrup, K. & D. G. Russell: Mycobacterial persistence: adaptation to a changing environment. Trends Microbiol. 9, 597-605 (2001)
14. Flynn, J. L. & J. Chan: Tuberculosis: latency and reactivation. Infect. Immun. 69, 4195-4201 (2001)
15. Ulrichs, T. & S. H. Kaufmann: Mycobacterial persistence and immunity. Front. Biosci. 7, d458-69 (2002)
16. Riska, P. F. & S. Carleton. Latent tuberculosis: models, mechanisms, and novel prospects for eradication. Semin. Pediatr. Infect. Dis. 13, 263-272 (2002)
17. Zahrt, T. C.: Molecular mechanisms regulating persistent Mycobacterium tuberculosis infection. Microbes Infect. 5, 159-167 (2003)
18. Gomez, J. E. & J. D. McKinney: Persistence and Drug Tolerance, in TUBERCULOSIS, 2nd ed, Ed., William N. Rom and Stuart Garay, Chapter 8, p. 101-114, Lippincott Williams & Wilkins, A Wolters Kluwer Company, New York (2003)
19. Wayne, L. G. & H. A. Sramek: Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38, 2054-2058 (1994)
20. Murugasu-Oei, B & T. Dick: Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG. J. Antimicrob. Chemother. 46, 917-919 (2000)
21. Mayuri, Bagchi, G., Das, T. K. & J. S. Tyagi: Molecular analysis of the dormancy response in Mycobacterium smegmatis: expression analysis of genes encoding the DevR-DevS two-component system, Rv3134c and chaperone alpha-crystallin homologues. FEMS Microbiol. Lett. 211, 231-237 (2002)
22. Sun, Z. & Y. Zhang: Spent culture supernatant of Mycobacterium tuberculosis H37Ra improves viability of aged cultures of this strain and allows small inocula to initiate growth. J. Bacteriol. 181, 7626-7628 (1999)
23. Zhang, Y., Y. Yang, A. Woods, R. J. Cotter & Z. Sun: Resuscitation of dormant Mycobacterium tuberculosis by phospholipids or specific peptides. Biochem. Biophys. Res. Commun. 284, 542-547 (2001)
24. Mukamolova, G. V., O. A. Turapov, D. I. Young, A. S. Kaprelyants, D. B. Kell, & M. Young: A family of autocrine growth factors in Mycobacterium tuberculosis. Mol. Microbiol. 46, 623-635 (2002)
25. Biketov, S., G. V. Mukamolova, V. Potapov, E. Gilenkov, G. Vostroknutova, D. B. Kell, M. Young & A. S. Kaprelyants: Culturability of Mycobacterium tuberculosis cells isolated from murine macrophages: a bacterial growth factor promotes recovery. FEMS Immunol. Med. Microbiol. 29, 233-240 (2000)
26. McCune, R. M., R. Tompsett & W. McDermott: The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by administration of pyrazinamide and a companion drug. J. Exp. Med. 104, 763-802 (1956)
27. McCune, R., S. H. Lee, K. Deuschle & W. McDermott: Ineffectiveness of isoniazid in modifying the phenomenon of microbial persistence. Am. Rev. Tuberc. 76, 1106-1109 (1957)
28. Orme I. M.: The latent tubercle bacillus (I'll let you know if I ever meet one). Int. J. Tuberc. Lung Dis. 5, 589-593 (2001)
29. Mazurek, G. H., P. A. LoBue, C. L. Daley, J. Bernardo, A. A. Lardizabal, W. R. Bishai, M. F. Iademarco & J. S. Rothel: Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 286, 1740-1747 (2001)
30. Mazurek, G. H. & M. E. Villarino: Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. Centers for Disease Control and Prevention. MMWR Recomm. Rep. 52(RR-2), 15-18 (2003)
31. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 161, S221-247 (2000)
32. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm. Rep. 49(RR-6), 1-51 (2000)
33. Lincoln, E. M.: Effect of antimicrobial therapy on prognosis of primary tuberculosis in childhood. Am. Rev. Tuberc. 69, 682-689 (1954)
34. Ferebee, S. H., F. W. Mount & A. A. Anastasiades: Prophylactic effects of isoniazid on primary tuberculosis in children. A preliminary report. Am. Rev. Tuberc. 76, 942-963 (1957)
35. Comstock, G. W., S. H. Ferebee & L. M. Hammes: A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am. Rev. Respir. Dis. 95, 935-943 (1967)
36. Bate, J.: The tuberculin skin test and treatment of latent tuberculosis infection, in TUBERCULOSIS, 2nd ed, Ed., William N. Rom and Stuart Garay, Chapter 55, p. 837-842, Lippincott Williams & Wilkins, A Wolters Kluwer Company, New York (2003)
37. Hill, A. R.: "Treatment of LTBI": selling point or semantic blunder? Am. J. Respir. Crit. Care Med. 165, 1338 (2002)
38. Katz, J., S. Kunofsky, V. Damijonaitis, A. Lafleur & T. Caron: Effect of isoniazid upon the reactivation of inactive tuberculosis; final report. Am. Rev. Respir. Dis. 91, 345-350 (1965)
39. Zhang, Y.: Isoniazid, in TUBERCULOSIS, 2nd ed, Ed., William N. Rom and Stuart Garay, Chapter 49, pp739-758, Lippincott Williams & Wilkins, A Wolters Kluwer Company, New York (2003)
40. Moat, A. G. & J. W. Foster: Microbial Physiology, Third edition, Wiley-Liss, A John Wiley & Sons, Inc. Publication, New York (1995)
41. Kolter, R, D. A. Siegele & A. Tormo: The stationary phase of the bacterial life cycle. Annu. Rev. Microbiol. 47, 855-874 (1993)
42. Zambrano, M. M. & R. Kolter: GASPing for life in stationary phase. Cell 86, 181-184 (1996)
43. Smeulders, M. J., J. Keer, R. A. Speight & H. D. Williams: Adaptation of Mycobacterium smegmatis to stationary phase. J. Bacteriol. 181, 270-283 (1999)
44. Rychlik, I., L. Cardova, M. Sevcik & P. A. Barrow: Flow cytometry characterisation of Salmonella typhimurium mutants defective in proton translocating proteins and stationary-phase growth phenotype. J. Microbiol. Methods 42, 255-263 (2000)
45. Kaprelyants, A. S. & D. B. Kell: Dormancy in stationary-phase cultures of Micrococcus luteus: flow cytometric analysis of starvation and resuscitation. Appl. Environ. Microbiol. 59, 3187-3196 (1993)
46. Mukamolova, G. V., A. S. Kaprelyants, D. I. Young, M. Young & D. B. Kell: A bacterial cytokine. Proc. Natl. Acad. Sci. USA 95, 8916-8921 (1998)
47. Nystrom, T.: Nonculturable bacteria: programmed survival forms or cells at death's door? Bioessays 25, 204-211 (2003)
48. Roszak, D.B. & R. R. Colwell: Metabolic activity of bacterial cells enumerated by direct viable count. Appl. Environ. Microbiol. 53, 2889-2893 (1987)
49. Wilson, G. S.: The proportion of viable bacteria in young cultures with especial reference to the technique employed in counting. J. Bacteriol. 7, 405-445 (1922)
50. Shleeva, M. O., K. Bagramyan, M. V. Telkov, G. V. Mukamolova, M. Young, D. B. Kell & A. S. Kaprelyants: Formation and resuscitation of "non-culturable" cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. Microbiology 148, 1581-1591 (2002)
51. Canetti, G.: The Tubercle Bacillus in the Pulmonary Lesion of Man. Springer Publishing Company, New York (1955)
52. Hobby, G. L., O. Auerbach, T. F. Lenert, M. J. Small & J. V. Comer: The late emergence of M. tuberculosis in liquid cultures of pulmonary lesions resected from humans. Am. Rev. Tuberc. 70, 191-218 (1954).
53. Medlar, E. M., S. Berstein, & D. M. Steward: A bacteriologic study of resected tuberculous lesions. Am. Rev. Tuberc. 66, 36-43 (1952)
54. Beck, F. & D. Yegian: A study of the tubercle bacillus in resected pulmonary lesions. Am. Rev. Tuberc. 66, 44-51 (1952).
55. Falk, A., W. B. Tucker, & J. E. Kaufman: A clinical and bacteriologic correlation of resected pulmonary tuberculous lesions. Am. Rev. Tuberc. 70, 689-700 (1954)
56. Wayne, L. G.: The bacteriology of resected tuberculous pulmonary lesions. II. Observations on bacilli which are stainable but which cannot be cultured. Am. Rev. Respir. Dis. 82, 370-377 (1960).
57. Much, H.: Die nach Ziel nicht darstellbaren Formen des Tuberkelbacillus. Berlin Klin. Wochenschr. 45, 691-694 (1908).
58. Sweany, H. C.: The granules of the tubercle bacillus. Am. Rev. Tuberc. 17, 53-76 (1928)
59. Sweany, H. C.: The filterability of the tubercle bacillus. Am. Rev. Tuberc. 17, 77-85 (1928)
60. Khomenko, A. G.: The variability of Mycobacterium tuberculosis in patients with cavitary pulmonary tuberculosis in the course of chemotherapy. Tubercle 68, 243-253 (1987)
61. Ratnam, S. & S. Chandrasekhar: The pathogenicity of spheroplasts of Mycobacterium tuberculosis. Am. Rev. Respir. Dis. 114, 549-554 (1976)
62. Chandrasekhar, S. & S. Ratnam: Studies on cell-wall deficient non-acid fast variants of Mycobacterium tuberculosis. Tuberc. Lung. Dis. 73, 273-279 (1992)
63. Domingue, G. J. & H. B. Woody: Bacterial persistence and expression of disease. Clin. Microbiol. Rev. 10, 320-344 (1997)
64. Fontes, A.: Uber die Filtrierbarkeit des Tuberkelvirus vom Standpunkte des Polymorphismus. Beitr. Klin. Tuberk. 77, 1-15 (1931)
65. Mellon, R. R. & L. W. Fisher: New studies on the filterability of pure cultures of the tubercle group of microorganisms. J. Infect. Dis. 51, 117-128 (1932).
66. Hernandez-Pando, R., M. Jeyanathan, G. Mengistu, D. Aguilar, H. Orozco, M. Harboe, G. A. Rook & G. Bjune: Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356, 2133-2138 (2000).
67. de Wit, D., M. Wootton, J. Dhillon & D. A. Mitchison: The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tuberc. Lung. Dis. 76, 555-562 (1995)
68. Pai, S. R., J. K. Actor, E. Sepulveda, R. L. Hunter & C. Jagannath: Identification of viable and non-viable Mycobacterium tuberculosis in mouse organs by directed RT-PCR for antigen 85B mRNA. Microb. Pathog. 28, 335-342 (2000)
69. Daley, C. Tuberculosis latency in humans, in TUBERCULOSIS - 2nd ed, Ed. William N. Rom and Stuart Garay, Chapter 7, p. 85-99, Lippincott Williams & Wilkins, A Wolters Kluwer Company, New York (2003)
70. McCune, R. M., R. Tompsett & W. McDermott: The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by administration of pyrazinamide and a companion drug. J. Exp. Med. 104, 763-802 (1956)
71. McCune, R. M., F. M. Feldman, H. Lambert & W. McDermott: Microbial persistence I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J. Exp. Med. 123, 445-468 (1966)
72. Scanga, C.A., V. P. Mohan, H. Joseph, K. Yu, J. Chan & J. L. Flynn: Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect. Immun. 67, 4531-4538 (1999)
73. Grosset, J., C. Truffot-Pernot, C. Lacroix & B. Ji: Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. 36, 548-551 (1992)
74. Wayne, L. G.: Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. Am. Rev. Respir. Dis. 114, 807-811 (1976)
75. Wayne, L. G. & K. Y. Lin: Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect. Immun. 37, 1042-1049 (1982)
76. Wayne, L. G. & L. G. Hayes: An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64, 2062-2069 (1996)
77. Wayne, L. G. & L. G. Hayes: Nitrate reduction as a marker for hypoxic shiftdown of Mycobacterium tuberculosis. Tuberc. Lung Dis. 79, 127-132 (1998)
78. Hu, Y. M., P. D. Butcher, K. Sole, D. A. Mitchison & A. R. Coates: Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol. Lett. 158, 139-145 (1998)
79. Hu, Y., J. A. Mangan, J. Dhillon, K. M. Sole, D. A. Mitchison, P. D. Butcher & A. R. Coates: Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J. Bacteriol. 182, 6358-6365 (2000)
80. McKinney, J. D., K. Höner Zu Bentrup, E. J. Munoz-Elias, A. Miczak, B. Chen, W. T. Chan, D. Swenson, J. C. Sacchettini, W. R. Jacobs, Jr. & D. G. Russell: Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406, 735-738 (2000)
81. Hong, P. C., R. M. Tsolis & T. A. Ficht: Identification of genes required for chronic persistence of Brucella abortus in mice. Infect. Immun. 68, 4102-4107 (2000)
82. Dhillon, J., B. W. Allen, Y. M. Hu, A. R. Coates & D. A. Mitchison: Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int. J. Tuberc. Lung Dis. 2, 736-742 (1998)
83. Brooks, J. V., S. K. Furney & I. M. Orme: Metronidazole therapy in mice infected with tuberculosis. Antimicrob. Agents Chemother. 43, 1285-1288 (1999)
84. DeMaio, J., Y. Zhang, C. Ko, D. B. Young & W. R. Bishai: A stationary-phase stress-response sigma factor from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U S A. 93, 2790-2794 (1996)
85. DeMaio. J., Y. Zhang, C. Ko & W. R. Bishai: Mycobacterium tuberculosis sigF is part of a gene cluster with similarities to the Bacillus subtilis sigF and sigB operons. Tuberc. Lung Dis. 78, 3-12 (1997)
86. Beaucher, J., S. Rodrigue, P. E. Jacques, I. Smith, R. Brzezinski & L. Gaudreau: Novel Mycobacterium tuberculosis anti-sigma factor antagonists control sigmaF activity by distinct mechanisms. Mol. Microbiol. 45, 1527-1540 (2002)
87. Michele, T. M., C. Ko & W. R. Bishai: Exposure to antibiotics induces expression of the Mycobacterium tuberculosis sigF gene: implications for chemotherapy against mycobacterial persistors. Antimicrob. Agents Chemother. 43, 218-225 (1999)
88. Chen, P., R. E. Ruiz, Q. Li, R. F. Silver & W. R. Bishai: Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate sigma factor gene, sigF. Infect. Immun. 68, 5575-5580 (2000)
89. Manganelli, R., E. Dubnau, S. Tyagi, F. R. Kramer & I. Smith: Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis. Mol. Microbiol. 31, 715-724 (1999)
90. Hu, Y. & A. R. Coates: Increased levels of sigJ mRNA in late stationary phase cultures of Mycobacterium tuberculosis detected by DNA array hybridisation. FEMS Microbiol. Lett. 202, 59-65 (2001)
91. Sherman, D. R., M. Voskuil, D. Schnappinger, R. Liao, M. I. Harrell & G. K. Schoolnik Regulation of the M. tuberculosis hypoxic response gene alpha-crystallin. Proc. Natl. Acad. Sci. USA 98, 7534-7539 (2001)
92. Graham, J. E. & J. E. Clark-Curtiss: Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proc. Natl. Acad. Sci. USA 96, 11554-11559 (1999)
93. Höner Zu Bentrup, K., A. Miczak, D. L. Swenson & D. G. Russell. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J. Bacteriol. 181, 7161-7167 (1999)
94. Fenhalls, G., L. Stevens, L. Moses, J. Bezuidenhout, J. C. Betts, P. van Helden, P. T. Lukey & K. Duncan: In situ detection of Mycobacterium tuberculosis transcripts in human lung granulomas reveals differential gene expression in necrotic lesions. Infect. Immun. 70, 6330-6338 (2002)
95. Lorenz, M. C. & G. R. Fink: The glyoxylate cycle is required for fungal virulence. Nature 412, 83-86 (2001)
96. Glickman, M. S., J. S. Cox & W. R. Jacobs Jr.: A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell 5, 717-727 (2000)
97. Yuan, Y., R. E. Lee, G. S. Besra, J. T. Belisle & C. E. Barry 3rd: Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 92, 6630-6634 (1995)
98. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, C. E. Barry III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLean, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Seeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, & B. G. Barrell. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544 (1998)
99. Young, R. A., B. R. Bloom, C. M. Grosskinsky, J. Ivanyi, D. Thomas & R. W. Davis: Dissection of Mycobacterium tuberculosis antigens using recombinant DNA. Proc. Natl. Acad. Sci. USA 82, 2583-2587 (1985)
100. Verbon, A., R. A. Hartskeerl, A. Schuitema, A. H. Kolk, D. B. Young & R. Lathigra: The 14,000-molecular-weight antigen of Mycobacterium tuberculosis is related to the alpha-crystallin family of low-molecular-weight heat shock proteins. J. Bacteriol. 174, 1352-1359 (1992)
101. Yuan, Y., D. D. Crane, C. E. Barry 3rd: Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog. J. Bacteriol. 178, 4484-4492 (1996)
102. Cunningham, A. F. & C. L. Spreadbury: Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J. Bacteriol. 180, 801-808 (1998)
103. rd: The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages. Proc. Natl. Acad. Sci. U S A 95, 9578-9583 (1998)
104. Desjardin, L. E., L. G. Hayes, C. D. Sohaskey, L. G. Wayne & K. D. Eisenach: Microaerophilic induction of the alpha-crystallin chaperone protein homologue (hspX) mRNA of Mycobacterium tuberculosis. J. Bacteriol. 183, 5311-5316 (2001)
105. Garbe, T. R., N. S. Hibler & V. Deretic: Response to reactive nitrogen intermediates in Mycobacterium tuberculosis: induction of the 16-kilodalton alpha-crystallin homolog by exposure to nitric oxide donors. Infect. Immun. 67, 460-465 (1999)
106. Monahan, I. M., J. Betts, D. K. Banerjee & P. D. Butcher: Differential expression of mycobacterial proteins following phagocytosis by macrophages. Microbiology 147, 459-471 (2001)
107. Boon, C. & T. Dick: Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J. Bacteriol. 184, 6760-6767 (2002)
108. Cashel, M., D. R. Gentry, V. J. Hernandez & D. Vinella: The stringent response, p. 1488-1496. In F. C. Neidhardt, R. Curtis, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed., vol. 1. ASM Press, Washington, D.C. (1996)
109. Avarbock, D., J. Salem, L. S. Li, Z. M. Wang & H. Rubin: Cloning and characterization of a bifunctional RelA/SpoT homologue from Mycobacterium tuberculosis. Gene 233, 261-269 (1999)
110. rd: The stringent response of Mycobacterium tuberculosis is required for long-term survival. J. Bacteriol. 182, 4889-4898 (2000)
111. rd: The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc. Natl. Acad. Sci. U S A 100, 10026-10031 (2003)
112. Ramakrishnan, L., N. A. Federspiel & S. Falkow: Granuloma-specific expression of mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science 288, 1436-1439 (2000)
113. Espitia, C., J. P. Laclette, M. Mondragon-Palomino, A. Amador, J. Campuzano, A. Martens, M. Singh, R. Cicero, Y. Zhang & C. Moreno: The PE-PGRS glycine-rich proteins of Mycobacterium tuberculosis: a new family of fibronectin-binding proteins? Microbiology 145, 3487-3495 (1999)
114. Brennan, M.J., G. Delogu, Y. Chen, S. Bardarov, J. Kriakov, M. Alavi & W. R. Jacobs Jr: Evidence that mycobacterial PE-PGRS proteins are cell surface constituents that influence interactions with other cells. Infect. Immun. 69, 7326-7633 (2001)
115. Banu, S., N. Honore, B. Saint-Joanis, D. Philpott, M. C. Prevost & S. T. Cole. Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Mol. Microbiol. 44, 9-19 (2002)
116. Brennan, M. J. & G. Delogu: The PE multigene family: a 'molecular mantra' for mycobacteria. Trends Microbiol. 10, 246-249 (2002)
117. Lim, A., M. Eleuterio, B. Hutter, B. Murugasu-Oei & T. Dick: Oxygen depletion-induced dormancy in Mycobacterium bovis BCG. J. Bacteriol. 181, 2252-2256 (1999)
118. Dasgupta, N., V. Kapur, K. K. Singh, T. K. Das, S. Sachdeva, K. Jyothisri & J. S. Tyagi: Characterization of a two-component system, devR-devS, of Mycobacterium tuberculosis. Tuberc. Lung Dis. 80, 141-159 (2000)
119. Park, H. D., K. M. Guinn, M. I. Harrell, R. Liao, M. I. Voskuil, M. Tompa, G. K. Schoolnik & D. R. Sherman: Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol. Microbiol. 48, 833-843 (2003)
120. Parish, T., D. A. Smith, S. Kendall, N. Casali, G. J. Bancroft & N. G. Stoker: Deletion of two-component regulatory systems increases the virulence of Mycobacterium tuberculosis. Infect. Immun. 71, 1134-1140 (2003)
121. O'Toole, R., M. J. Smeulders, M. C. Blokpoel, E. J. Kay, K. Lougheed K & H. D. Williams: A two-component regulator of universal stress protein expression and adaptation to oxygen starvation in Mycobacterium smegmatis. J. Bacteriol. 185, 1543-1554 (2003)
122. Hutter, B. & T. Dick. Up-regulation of narX, encoding a putative 'fused nitrate reductase' in anaerobic dormant Mycobacterium bovis BCG. FEMS Microbiol. Lett. 178, 63-69 (1999)
123. Hutter, B. & T. Dick: Analysis of the dormancy-inducible narK2 promoter in Mycobacterium bovis BCG. FEMS Microbiol. Lett. 188, 141-146 (2000)
124. Fritz, C., S. Maass, A. Kreft & F. C. Bange: Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific. Infect. Immun. 70, 286-291 (2002)
125. rd & P. Andersen: Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. J. Bacteriol. 184, 3485-3491 (2002)
126. Betts, J. C., P. T. Lukey, L. C. Robb, R. A. McAdam & K. Duncan: Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43, 717-731 (2002)
127. Dubos, R. J., & B. D. Davis: Factors affecting the growth of tubercle bacilli in liquid media. J. Exp. Med. 83, 409-423 (1946)
128. Hobby, G. L., K. Meyer & E. Chaffee: Observations on the mechanism of penicillin. Proc. Soc. Exper. Biol. Med. 50, 281-285 (1942).
129. Kondo, E. & K. Kanai: [Studies on the relationship between the proliferation rate of infecting tubercle bacilli and the effectiveness of chemotherapy. I. Observations in a mouse experimental model using a streptomycin-dependent strain (author's transl)]. Kekkaku 52, 411-415 (1977)
130. Stewart, P. S.: Mechanisms of antibiotic resistance in bacterial biofilms. Int. J. Med. Microbiol. 292, 107-113 (2002)
131. Hogan, D. & R. Kolter: Why are bacteria refractory to antimicrobials? Curr. Opin. Microbiol. 5, 472-477 (2002)
132. Lewis, K.: Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45, 999-1007 (2001)
133. Zhang, Y. & L. M. Amzel: Tuberculosis drug targets. Curr. Drug Targets 3, 131-154 (2002)
134. Greenway, D. L. & R. R. England: The intrinsic resistance of Escherichia coli to various antimicrobial agents requires ppGpp and sigma S. Lett. Appl. Microbiol. 29, 323-326 (1999)
135. Demerec, M.: Origin of bacterial resistance to antibiotics. J. Bacteriol. 56, 63-74 (1948)
136. Booth, I. R.: Stress and the single cell: intrapopulation diversity is a mechanism to ensure survival upon exposure to stress. Int. J. Food Microbiol. 78, 19-30 (2002)
137. Debbia, E. A., S. Roveta, A. M. Schito, L. Gualco & A. Marchese: Antibiotic persistence: the role of spontaneous DNA repair response. Microb. Drug Resist. 7, 335-342 (2001)
138. Mitchison, D. A.: Treatment of tuberculosis. The Mitchell lecture 1979. J. R. Coll. Physicians Lond. 14, 91-95, 98-99 (1980)
139. Jindani, A., V. R. Aber, E. A. Edwards & D. A. Mitchison: The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121, 939-949 (1980)
140. Wallis, R. S., S. Patil, S. H. Cheon, K. Edmonds, M. Phillips, M. D. Perkins, M. Joloba, A. Namale, J. L. Johnson, L. Teixeira, R. Dietze, S. Siddiqi, R. D. Mugerwa, K. Eisenach & J. J. Ellner: Drug tolerance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43, 2600-2606 (1999)
141. Pagel, W.: Reactivation of a tuberculous focus by microorganisms other than the tubercle bacillus. Lancet 1, 1279-1280 (1937)
142. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. East African and British Medical Research Councils. Lancet 2(8085), 334-338 (1978)
143. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. Am. Rev. Respir. Dis. 134, 27-33 (1986)
144. Balasubramanian, R., S. Sivasubramanian, V. K. Vijayan, R. Ramachandran, M. S. Jawahar, C. N. Paramasivan, N. Selvakumar & P. R. Somasundaram: Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. Tubercle 71, 253-258 (1990)
145. Orme, I. M.: A mouse model of the recrudescence of latent tuberculosis in the elderly. Am. Rev. Respir. Dis. 137, 716-718 (1988)
146. Adams, L. B., C. M. Mason, J. K. Kolls, D. Scollard, J. L. Krahenbuhl & S. Nelson: Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus. J. Infect. Dis. 171, 400-405 (1995)
147. Arriaga, A. K., E. H. Orozco, L. D. Aguilar, G. A. Rook & R. Hernandez Pando: Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis. Clin. Exp. Immunol. 128, 229-237 (2002)
148. Brown, D. H., B. A. Miles & B. S. Zwilling: Growth of Mycobacterium tuberculosis in BCG-resistant and - susceptible mice: establishment of latency and reactivation. Infect. Immun. 63, 2243-2247 (1995)
149. Capuano, S. V., D. A. Croix, S. Pawar, A. Zinovik, A. Myers, P. L. Lin, S. Bissel, C. Fuhrman, E. Klein & J. L. Flynn: Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infect. Immun. 71, 5831-5844 (2003)
150. Lillebaek, T., A. Dirksen, I. Baess, B. Strunge, V. O. Thomsen & A. B. Andersen: Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J. Infect. Dis. 185, 401-404 (2002)
151. Cox, J. H., B. C. Knight & J. Ivanyi: Mechanisms of recrudescence of Mycobacterium bovis BCG infection in mice. Infect. Immun. 57, 1719-1724 (1989)
152. Scanga, C.A., V. P. Mohan, K. Yu, H. Joseph, K. Tanaka, J. Chan & J. L. Flynn: Depletion of CD4(+) T cells causes reactivation of murine persistent tuberculosis despite continued expression of interferon gamma and nitric oxide synthase 2. J. Exp. Med. 192, 347-358 (2000)
153. van Pinxteren, L. A., J. P. Cassidy, B. H. Smedegaard, E. M. Agger & P. Andersen: Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30, 3689-3698 (2000)
154. Howard, A. D. & B. S. Zwilling: Reactivation of tuberculosis is associated with a shift from type 1 to type 2 cytokines. Clin. Exp. Immunol. 115, 428-434 (1999)
155. Bodnar, K. A., N. V. Serbina & J. L. Flynn: Fate of Mycobacterium tuberculosis within murine dendritic cells. Infect. Immun. 69, 800-809 (2001)
156. Pancholi, P., A. Mirza, N. Bhardwaj & R. M. Steinman: Sequestration from immune CD4+ T cells of mycobacteria growing in human macrophages. Science 260, 984-986. (1993)
157. Hmama, Z., R. Gabathuler, W. A. Jefferies, G. de Jong & N. E. Reiner: Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. J. Immunol. 161, 4882-4893 (1998)
158. Noss, E. H., C. V. Harding & W. H. Boom:. Mycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophages. Cell. Immunol. 201, 63-74 (2000)
159. Hirsch, C. S., R. Hussain, Z. Toossi, G. Dawood, F. Shahid & J. J. Ellner. Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. Proc. Natl. Acad. Sci. USA 93, 3193-3198 (1996)
160. Rojas, R. E., K. N. Balaji, A. Subramanian & W. H. Boom: Regulation of human CD4(+) alphabeta T-cell-receptor-positive (TCR(+)) and gammadelta TCR(+) T-cell responses to Mycobacterium tuberculosis by interleukin-10 and transforming growth factor beta. Infect. Immun. 67, 6461-6472 (1999)
161. Turner, J., M. Gonzalez-Juarrero, D. L. Ellis, R. J. Basaraba, A. Kipnis, I. M. Orme & A. M. Cooper: In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J. Immunol. 169, 6343-6351 (2002)
162. Hernandez-Garay, M. & P. Mendez-Samperio: Transforming growth factor-beta decreases survival of Mycobacterium bovis-activated T cells. Arch. Med. Res. 34, 20-25 (2003)
163. Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach & D. L. Sacks: CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507 (2002)
164. Hernandez-Pando, R. & G. A. Rook: The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 82, 591-595 (1994)
165. Flynn, J. L., M. M. Goldstein, J. Chan, K. J. Triebold, K. Pfeffer, C. J. Lowenstein, R. Schreiber, T. W. Mak & B. R. Bloom: Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2, 561-572 (1995)
166. Bean, A. G., D. R. Roach, H. Briscoe, M. P. France, H. Korner, J. D. Sedgwick & W. J. Britton: Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162, 3504-3511 (1999)
167. Mohan, V.P., C. A. Scanga, K. Yu, H. M. Scott, K. E. Tanaka, E. Tsang, M. M. Tsai, J. L. Flynn & J. Chan: Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69, 1847-1855 (2001)
168. Maini, R., E. W. St Clair, F. Breedveld, D. Furst, J. Kalden, M. Weisman, J. Smolen, P. Emery, G. Harriman, M. Feldmann & P. Lipsky: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Study Group. Lancet 354(9194), 1932-1939 (1999)
169. Keane, J., S. Gershon, R. P. Wise, E. Mirabile-Levens, J. Kasznica, W. D. Schwieterman, J. N. Siegel & M. M. Braun: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345, 1098-1104 (2001)
170. Nunez Martinez, O., C. Ripoll Noiseux, J. A. Carneros Martin, V. Gonzalez Lara, H. G. Gregorio Maranon: Reactivation tuberculosis in a patient with anti-TNF-alpha treatment. Am. J. Gastroenterol. 96, 1665-1666 (2001)
171. Wagner, T. E., E. S. Huseby & J. S. Huseby: Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-alpha inhibitor. Am. J. Med. 112, 67-69 (2002)
172. Mayordomo, L., J. L. Marenco, J. Gomez-Mateos & E. Rejon: Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand. J. Rheumatol. 31, 44-45 (2002)
173. Roth, S., E. Delmont, P. Heudier, R. Kaphan, E. Cua, J. Castela, J. M. Verdier, R. M. Chichmanian & J. G. Fuzibet: Anti-TNF alpha monoclonal antibodies (infliximab) and tuberculosis: apropos of 3 cases [Article in French]. Rev. Med. Interne. 23, 312-316 (2002)
174. Chan, J., Y. Xing, R. S. Magliozzo & B. R. Bloom: Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175, 1111-1122 (1992)
175. Flynn, J. L., C. A. Scanga, K. E. Tanaka & J. Chan: Effects of aminoguanidine on latent murine tuberculosis. J. Immunol. 160, 1796-1803 (1998)
176. Botha, T. & B. Ryffel: Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model. Immunology 107, 350-357 (2002)
177. Berle, B. B.: Emotional factors and tuberculosis: A critical review of the literature. Psychosom. Med. 10, 366-373 (1948)
178. Wittkower, E. D.: Psychological aspects of tuberculosis. Am. Rev. Tuberc. 67, 869-873 (1953)
179. Clarke, E. R., D. W. Zahn & T. H. Holmes: The relationship of stress, adrenocortical function, and tuberculosis. Am. Rev. Tuberc. 69, 351-369 (1954)
180. Dubos, R. & J. Dubos: The White Plague: Tuberculosis, Man, and Society. Rutgers University Press, New Brunswick, N. J. (1987)
181. Ryan, F.: The Forgotten Plague. How the Battle against Tuberculosis Was Won - and Lost, p155-156, Little, Brown and Company (1993)
182. Pecyna, M. B. & A. Hryniewiecka: [The role of psychological factors in the etiopathogenesis of pulmonary tuberculosis] [Article in Polish] Pol. Tyg. Lek. 43, 850-853 (1988)
183. Rogowski, J., K. Mulak, W. Nartowska, Z. Piasecki & B. Kadrys: [Psychological and social factors in the recurrence of pulmonary tuberculosis][Article in Polish] Pneumonol. Pol. 48, 685-692 (1980)
184. Lukashova, E. N., L. N. Igisheva & I. F. Kopylova: [Psychological peculiarities in adolescent patients with tuberculosis][Article in Russian] Probl. Tuberk. 1, 39-41 (2002)
185. Dai, G., S. Phalen & D. N. McMurray: Nutritional modulation of host responses to mycobacteria. Front. Biosci. 3, E110-122 (1998)
186. Yang, E.V. & R. Glaser: Stress-induced immunomodulation and the implications for health. Int. Immunopharmacol. 2, 315-324 (2002)
187. Biondi, M. & L. G. Zannino: Psychological stress, neuroimmunomodulation, and susceptibility to infectious diseases in animals and man: a review. Psychother. Psychosom. 66, 3-26 (1997)
188. Wyser, C., G. Walzl, J. P. Smedema, F. Swart, E. M. van Schalkwyk & B. W. van de Wal: Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest 110, 333-338 (1996)
189. Smego, R. A. & N. Ahmed: A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 7, 208-213 (2003)
190. Dooley, D. P., J. L. Carpenter & S. Rademacher: Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin. Infect. Dis. 25, 872-887 (1997)
191. Tam, L. S., E. K. Li, S. M. Wong & C. C. Szeto: Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand. J. Rheumatol. 31, 296-300 (2002)
192. Chan, Y. C. & G. Yosipovitch: Suggested guidelines for screening and management of tuberculosis in patients taking oral glucocorticoids - an important but often neglected issue. J. Am. Acad. Dermatol. 49, 91-95 (2003)
193. Hernandez-Pando, R., M. De La Luz Streber, H. Orozco, K. Arriaga, L. Pavon, S. A. Al-Nakhli & G. A. Rook: The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice. Immunology 95, 234-241 (1998)
194. Yamagishi, F., Y. Sasaki, T. Yagi, H. Yamatani, F. Kuroda & H. Shoda: Frequency of complication of diabetes mellitus in pulmonary tuberculosis. Kekkaku 75, 435-437 (2000)
195. Kado, S., T. Isobe, S. Ishioka, M. Yamakido, Y. Shibata & T. Kuraoka: Clinical feature of the diabetic patients with recurrent pulmonary tuberculosis. Kekkaku 67, 313-318 (1992)
196. Wada, M.: The effectiveness of pyrazinamide-containing six-month short course chemotherapy. Kekkaku 75, 665-673 (2000)
197. Steger, R. W. & M. B. Rabe: The effect of diabetes mellitus on endocrine and reproductive function. Proc. Soc. Exp. Biol. Med. 214, 1-11 (1997)
198. Smurova, T. F. & I. L. Egorova: Endocrine disorders and principles of their correction in patients with pulmonary tuberculosis and concomitant diabetes mellitus. Klin. Med. (Mosk) 71, 58-62 (1993)
199. Chan, O., K. Inouye, M. C. Riddell, M. Vranic & S. G. Matthews: Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol. 28, 87-102 (2003)
200. Tsukaguchi, K., T. Yoneda, M. Yoshikawa, T. Tokuyama, A. Fu, K. Tomoda, N. Narita, Y. Enoki, M. Tsukaguchi & F. Shirai F et al.: Case study of interleukin-1 beta, tumor necrosis factor alpha and interleukin-6 production peripheral blood monocytes in patients with diabetes mellitus complicated by pulmonary tuberculosis. Kekkaku 67, 755-760 (1992)
201. Hernandez-Pando, R., L. Pavon, E. H. Orozco, J. Rangel & G. A. Rook: Interactions between hormone-mediated and vaccine-mediated immunotherapy for pulmonary tuberculosis in BALB/c mice. Immunology 100, 391-398 (2000)
202. Morgan, W.K.: The relationship between tuberculosis and silicosis. Am. Rev. Respir. Dis. 119, 319-320 (1979)
203. Vorwald, A. J., M. Dworski & P. C. Pratt: The use of quartz dust for challenging the viability of tubercle bacilli in tuberculous lesions. Am. Rev. Respir. Dis. 69, 841-842 (1954)
204. Allison, A. C. & P. D. Hart: Potentiation by silica of the growth of Mycobacterium tuberculosis in macrophage cultures. Br. J. Exp. Pathol. 49, 465-476 (1968)
205. Yucesoy, B., V. Vallyathan, D. P. Landsittel, D. S. Sharp, A. Weston, G. R. Burleson, P. Simeonova, M. McKinstry & M. I. Luster: Association of tumor necrosis factor-alpha and interleukin-1 gene polymorphisms with silicosis. Toxicol. Appl. Pharmacol. 172, 75-82 (2001)
206. Zhang, Y. & D. Mitchison: The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7, 6-21 (2003)
207. Zhang, Y., A. Scorpio, H. Nikaido & Z. Sun: Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181, 2044-2049 (1999)
208. Zhang, Y., H. Zhang & Z. Sun: Susceptibility of Mycobacterium tuberculosis to weak acids. J. Antimicrob. Chemother. 52, 56-60 (2003)
209. Zhang, Y., M. W. Wade, A. Scorpio, H. Zhang & Z. Sun: Mode of action of pyrazinamide: Disruption of membrane potential and transport by pyrazinamide. J. Antimicrob. Chemother. 52, 790-795 (2003)
210. Sharma, V., S. Sharma, K. Hoener zu Bentrup, J. D. McKinney, D. G. Russell, W. R. Jacobs Jr & J. C. Sacchettini: Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat. Struct. Biol. 7, 663-668 (2000)
211. Huang, C. C., C. V. Smith, M. S. Glickman, W. R. Jacobs Jr & J. C. Sacchettini: Crystal structures of mycolic acid cyclopropane synthases from Mycobacterium tuberculosis. J. Biol. Chem. 277, 11559-11569 (2002)
212. Brown, M. R. & A. W. Smith: Dormancy and persistence in chronic infection: role of the general stress response in resistance to chemotherapy. J. Antimicrob. Chemother. 48, 141-142 (2001)
213. Coates, A., Y. Hu, R. Bax and C. Page: The future challenges facing the development of new antimicrobial drugs. Nat. Rev. Drug Discov. 1, 895-910 (2002)
214. Lowrie, D. B., R. E. Tascon, V. L. Bonato, V. M. Lima, L. H. Faccioli, E. Stavropoulos, M. J. Colston, R. G. Hewinson, K. Moelling K & C. L. Silva: Therapy of tuberculosis in mice by DNA vaccination. Nature 400, 269-271 (1999)
215. Repique, C. J., A. Li, F. M. Collins & S. L. Morris: DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge. Infect. Immun. 70, 3318-3323 (2002)
216. Taylor, J. L., O. C. Turner, R. J. Basaraba, J. T. Belisle, K. Huygen & I. M. Orme: Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. 71, 2192-2198 (2003)
217. Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle 64, 73-91 (1983)
218. Rook, G. A. & R. Hernandez-Pando: Immunological and endocrinological characteristics of tuberculosis that provide opportunities for immunotherapeutic intervention. Novartis Found. Symp. 217, 73-87 (1998)
219. Dhillon, J. & D. A. Mitchison: Effect of vaccines in a murine model of dormant tuberculosis. Tuber. Lung Dis. 75, 61-64 (1994)
220. Wu, X. et al., Poster presented at the Fourth World Congress on Tuberculosis, June 3-5, Washington, D.C. (2002)
221. Holland, S. M.: Cytokine therapy of mycobacterial infections. Adv. Intern. Med. 45, 431-452 (2000)